1. The CDMO Market: Size, Consolidation, and the IP Stakes That Changed Everything The global contract development and manufacturing organization […]
A technical deep dive for IP teams, portfolio managers, R&D leads, and institutional investors in biologics and biosimilar development. Why
Biosimilar Regulatory Strategy: The Complete Playbook for FDA, EMA, and Global Approval Read Post »
A single drug can generate $10 billion in annual revenue. The same drug, one day after its last relevant patent
“The average branded drug loses roughly 80% of its revenue within 12 months of generic entry. What happens in the
Drug Patent Expirations: The $236 Billion Investment Playbook Read Post »
Russia’s Drug Machine: Inside the Industry That Rewired Itself Overnight In 2024, the total value of the market reached 2.85
Inside the Russian Pharma Industry: Key Players and Innovations Read Post »
How patent cliffs, dual disease burdens, and a rising global middle class are redrawing the map of pharmaceutical competition —
The median pharmaceutical patent case where more than $25 million is at risk costs $4 million to litigate through trial
Drug Patent Litigation Costs: The $5M Playbook Pharma Executives Actually Use Read Post »
A technical deep dive for professionals who need more than a checklist. This is the architecture of a market-winning generic
For pharma IP teams, portfolio managers, R&D leads, and institutional investors tracking the $72B biosimilar market. 1. Executive Summary and
Sign in or create a free account to read this DrugPatentWatch article
